Protagenic therapeutics initiates phase i/iia clinical trial for groundbreaking brain peptide pt00114

A potential major step toward treating stress-related neuro-psychiatric disorders new york, ny / accesswire / september 26, 2023 / today, protagenic therapeutics, inc. (nasdaq:ptix), a pioneering biopharmaceutical company, has announced the commencement of its phase i/iia clinical trial for pt00114, its leading drug candidate. key highlights: clinical trial focus: the trial aims to evaluate the therapeutic potential of pt00114, a synthetic version of the naturally occurring brain peptide tcap, in treating an array of neuro-psychiatric conditions, including depression, anxiety, and ptsd.
PTIX Ratings Summary
PTIX Quant Ranking